3D Bioprinting Station
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 75N95022Q00443
- Agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
Notice details come from SAM.gov. Updated .
About this opportunity
The National Center for Advancing Translational Sciences within the National Institutes of Health National Institute on Drug Abuse seeks to acquire one Regenhu 3D Bioprinting Station model R-GEN 200 or equal through a firm-fixed price purchase order. The bioprinting station must meet technical specifications for developing biofabricated tissue models in support of research programs involving neuronal circuits, neuromuscular junctions, pain, addiction, and other disease models. Proposals are due by September 6, 2022 and will be evaluated based on meeting requirements, delivery approach, warranties, and past performance.
There is no set-aside designation. The solicitation is covered under NAICS code 334516 and PSC code 6515. The bioprinting station will be used at the agency's 3D Tissue Bioprinting Laboratory to increase capabilities for producing tissue models. The award value is estimated at $200,000 for one bioprinting station to be delivered within 90 days of order receipt. The place of performance will be the National Institutes of Health campus in Bethesda, Maryland.
Notice text
The 3D Tissue Bioprinting Laboratory (3DTBL) at the National Center for Advancing Translational Sciences (NCATS) is producing and using engineered tissues as physiological relevant assay platforms for predictive drugs screening. There is a need to purchase a new bioprinter which will be used to increase the capabilities of the group to develop biofabricated tissue models, including neuronal circuits of addiction and pain (HEAL program), neuromuscular junction (NMJ) tissue for muscular dystrophy-related diseases (potential application for gene therapy, like congenital myasthenic syndrome (CMS) for PaVe-GT program), and pain (HEAL program), vascularized lung models for the Antiviral Pandemic Program (APP), and tissue for the two programs funded by the RFA-TR-21-015.
The purpose of this acquisition is to acquire one (1) of Regenhu’s 3D Bioprinting Station model R-GEN 200 or Equal that meet all salient characteristics.
Attachments
| File | Type | Posted |
|---|---|---|
| 75N95022Q00443 - Amendment 1.pdf | ||
| Attachment 1 - Purchase Description.pdf | ||
| Attachment 2 - FAR 52.212-1 FAR 52.212-2.pdf | ||
| Attachment 6 - Invoice Instructions (IPP and non-IPP).pdf | ||
| 75N95022Q00443_CSS.pdf | ||
| Attachment 3 - FAR 52.212-5 (May 2022) print.pdf | ||
| Attachment 5 - Buy American Certificate.pdf | ||
| Attachment 4 - FAR 52.204-24, 52.204-26, and 52.212-3 Reps and Certs.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| 3D Bioprinting Station | Award Notice | |
| 3D Bioprinting Station | Solicitation | |
| 3D Bioprinting Station | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity